These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 2416266)

  • 1. Immunological complications in multiple sclerosis patients receiving interferon.
    Rice GP; Woelfel EL; Talbot PJ; Braheny SL; Sipe JC; Knobler RL; Merigan TC; Oldstone MB
    Ann Neurol; 1985 Oct; 18(4):439-42. PubMed ID: 2416266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon.
    Panitch HS; Francis GS; Hooper CJ; Merigan TC; Johnson KP
    Ann Neurol; 1985 Oct; 18(4):434-8. PubMed ID: 2416265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis].
    Seres E; Vécsei L
    Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.
    Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E
    Brain; 2008 Jun; 131(Pt 6):1455-63. PubMed ID: 18474519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cell activity in patients with multiple sclerosis given alpha interferon.
    Rice GP; Casali P; Merigan TC; Oldstone MB
    Ann Neurol; 1983 Sep; 14(3):333-8. PubMed ID: 6638954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of immune-complex size and antigen-antibody ratio on immune complex detection with monoclonal rheumatoid factor and C1q.
    Vanham G; Bloemmen FJ; Ceuppens JL; Stevens EA
    J Clin Lab Immunol; 1984 Oct; 15(2):63-8. PubMed ID: 6335179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antibodies against encephalitogenic protein and myelin glycoprotein in the cerebrospinal fluid of patients with multiple sclerosis. Effect of encorton treatment on the autoantibody and immune complex levels].
    Waigt A; Górny MK
    Folia Med Cracov; 1984; 25(3-4):307-18. PubMed ID: 6085729
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune complexes in systemic sclerosis; detection by C1q binding, K-cell inhibition and Raji cell radioimmunoassays.
    Hughes P; Cunningham J; Day M; Fitzgerald JC; French MA; Wright JK; Rowell NR
    J Clin Lab Immunol; 1983 Mar; 10(3):133-8. PubMed ID: 6601718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic effects of interferons: relevance to multiple sclerosis.
    Rudick RA; Ransohoff RM
    Mult Scler; 1995; 1 Suppl 1():S12-6. PubMed ID: 9345391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of natalizumab on the innate and adaptive immune system in the central nervous system.
    Stüve O
    J Neurol Sci; 2008 Nov; 274(1-2):39-41. PubMed ID: 18474372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple sclerosis immune complexes: an analysis of component antigens and antibodies.
    Coyle PK; Procyk-Dougherty Z
    Ann Neurol; 1984 Dec; 16(6):660-7. PubMed ID: 6098217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon alpha treatment of relapsing-remitting multiple sclerosis: long-term study of the correlations between clinical and magnetic resonance imaging results and effects on the immune function.
    Durelli L; Bongioanni MR; Cavallo R; Ferrero B; Ferri R; Verdun E; Bradac GB; Riva A; Geuna M; Bergamini L
    Mult Scler; 1995; 1 Suppl 1():S32-7. PubMed ID: 9345396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactivity of low molecular weight material in cellular immune complex assays.
    Cooper KM; Moore M
    Clin Exp Immunol; 1983 May; 52(2):407-16. PubMed ID: 6602679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis.
    Pellegrini P; Totaro R; Contasta I; Berghella AM; Carolei A; Adorno D
    Neuroimmunomodulation; 2005; 12(4):220-34. PubMed ID: 15990453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
    Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
    Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clq binding circulating immune complexes in multiple sclerosis patients and their first-degree relatives: a distinctive immunological feature between sporadic and familial cases.
    Trouillas P; Vincent C; Revillard JV
    J Clin Lab Immunol; 1980 Sep; 4(2):77-81. PubMed ID: 7441712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
    Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells from multiple sclerosis patients.
    Pentón-Rol G; Cervantes-Llanos M; Cabrera-Gómez JA; Alonso-Ramírez R; Valenzuela-Silva C; Rodríguez-Lara R; Montero-Casimiro E; Bello-Rivero I; López-Saura P
    Int Immunopharmacol; 2008 Jun; 8(6):881-6. PubMed ID: 18442793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Actual status of multiple sclerosis in Cuba. National cooperative group for the clinical trial "Recombinant interferon alpha-2b in multiple sclerosis"].
    Cabrera-Gómez JA; Santana-Capote E; Echazábal-Santana N; Díaz de la Fe A; Casanova M; Gómez L; Báez-Martín MM; González-Quevedo A; Fernández R; Vals O; Peña A; Rodríguez A; Cabrera-Núñez JA; Moscoso ME; Ruiz M
    Rev Neurol; 2000 Sep 1-15; 31(5):482-93. PubMed ID: 11027103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.